LPAR1 and thyroid cancer: Therefore, further investigations into whether the MAPK pathway truly represents a downstream substrate of LPAR1 and whether the regulation of the MAPK pathway by LPAR1 contributes to the promotion of resistance to anlotinib in thyroid cancer are imperative.